ClinicalTrials.gg
CompletedNCT00174668GINGERUpdated Sep 15, 2009

Insulin Glulisine in Diabetes Mellitus, Type 2

A Phase 3 interventional study of Insulin Glulisine and Insulin Therapy in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 15 sites in 15 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2009-09-15.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
311
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. insulin glulisine · Diabetes Mellitus, Type 2.

Enrollment
11th of 25
311 · median 281
Started
2004
with 5 others
Phase 3
8 of 26
none open now
Registered
5th of 26
by date
Lead sponsor
19 of 26
Sanofi

Among the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2004, is one of 8 in phase 3, and was the 5th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About insulin glulisine

insulin glulisine: first FDA approval 2004 (APIDRA SOLOSTAR), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 as a file.
02

Study summary

Primary objective:

The primary study objective is to demonstrate superior efficacy of an intensified insulin regimen with insulin glulisine and insulin glargine to a two-injection conventional insulin regimen in terms of change in glycated hemoglobin A1c (HbA1c), from baseline to endpoint.

Secondary objectives:

Secondary study objectives are to compare the intensified insulin regimen with insulin glulisine and insulin glargine to a two-injection conventional insulin regimen in terms of blood glucose (BG) values (fasting, pre-/postprandial (ppBG), nocturnal, mean daily, fasting plasma glucose), daily BG profiles, BG and HbA1c response rates (predefined), hypoglycemic events, adverse events, change of late diabetes complications, weight, body-mass-index, course of total daily insulin dose and adjustment, blood lipid profile, microalbuminuria, standard lab and quality of life/treatment satisfaction.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects meeting all of the following criteria will be considered for enrollment into the study:

  • Type 2 diabetes mellitus, as defined by the American Diabetes Association for at least five years, treated with insulin for at least 6 months (no history of ketoacidosis).
  • between 7.5% and 11.0%, inclusive at both pre-screening and pre-randomization (week -2).
  • For at least 3 months prior to week -8 visit, subjects must have been on a stable insulin regimen with two daily s.c. injections of premixed insulin: NPH plus regular insulin or NPH plus rapid acting insulin (insulin lispro or insulin aspart) in a mixture of 70/30 or 75/25. "Stable" means no change in regimen and no more than 30 % change in dose. Optionally, the subject can have been treated in addition with metformin according to its current official product information leaflet, treatment with other oral blood glucose lowering drugs is not allowed.
  • Documentation of a full ophthalmologic exam (incl. fundoscopy)during the 6 months prior to randomization.
  • Women are either not of (surgically sterile, or for more than 2 years). Women of childbearing potential must not be pregnant and agree to use a reliable measure for the duration of the study. Reliable contraceptive measures include the following: systemic contraceptive (oral, implant, injections), diaphragm with intravaginal spermicide, cervical cap, intrauterine device or condom with spermicide.
  • Willing and able to perform specified home blood glucose monitoring and to otherwise comply with study protocol requirements.
  • Willing to change from a twice daily insulin regimen to a regimen requiring four daily insulin injections.
  • Provision of signed and dated prior to any study procedures."Prescreening" informed consent, obtained in writing for all subjects, may be used during screening, but full study-specific informed consent must be obtained in writing for all subjects after any post-screening procedures.

Exclusion criteria

Exclusion criteria :

Subjects presenting with any of the following will not be included in the study:

  • Two or more severe hypoglycemic episodes within the past 3 months, or any hospitalization or emergency room visit due to poor diabetic control within the past 3 months prior to randomization.
  • History of hypoglycemia unawareness.
  • Impaired hepatic function, as shown by, but not limited to, ALAT () or ASAT (SGOT) above 2x the as measured at visit 1.
  • Impaired renal function, as shown by, but not limited to, serum creatinine > 177 mmol/l (> 2 mg/dl) as measured at visit 1 (if no lower values due to individual metformin intake are required) or current renal dialysis.
  • (BMI) > 38 kg/m2.
  • Any other abnormalities on screening laboratory evaluation (unless discussed with the monitor and approved by the study management).
  • Active proliferative diabetic retinopathy, as defined by the application of focal or panretinal photocoagulation or vitrectomy, in the 6 months prior to visit 1, or any other unstable (rapidly progressing) retinopathy that may require surgical treatment (including laser photocoagulation) during the study.
  • History of to insulin or insulin analogues or any of the in the HMR 1964 formulation.
  • Donation of blood or transfusion during the 2 months prior to the screening visit.
  • Pregnant or lactating women, or women planning to become pregnant during the study.
  • Treatment with any drug in the last month before visit 1 (screening).
  • Mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study.
  • Any clinically significant major organ system disease such as relevant cardiovascular, gastrointestinal, hepatic, neurologic, endocrine, hematologic or other major systemic diseases making implementation of the protocol or interpretation of the study results difficult.
  • Treatment or likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol.
  • History of drug or alcohol abuse within the last 2 years or current addiction to substances of abuse.
  • Night shift workers.
  • Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study.
  • Subject is the investigator or any subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
311 participants (actual)

Study arms

  • Experimental
    1

    Mealtime insulin glulisine 3x daily and insulin glargine 1 x daily subcutaneously

    Drug: Insulin Glulisine · Drug: Insulin Glargine

  • Active comparator
    2

    Two daily injection conventional insulin therapy

    Drug: Insulin Therapy

Interventions

  • insulin glulisine 3 x daily (TID) subcutaneously 15 min before the start of a meal

  • DrugInsulin Therapy

    NPH (70%) plus regular insulin or insulin aspart (30%)

  • 1 x daily (OD) subcutaneously at any time (but every day at the same time) according to BG

06

What researchers measure

Primary outcomes

  1. HbA1c

    Time frame: From baseline to study endpoint

  2. Self monitored BG (SMBG) values

    Time frame: During the whole treatment phase

  3. Body weight/body mass index (BMI)

    Time frame: From baseline to study endpoint and all other visits

  4. Fasting blood lipid profile

    Time frame: From baseline to study endpoint and all other visits

  5. Urine albumin

    Time frame: From baseline to study endpoint and all other visits

  6. Total daily insulin dose

    Time frame: From baseline to study endpoint

Secondary outcomes

  1. Adverse events

    Time frame: Throughout the study,

  2. Standard laboratory tests

    Time frame: From baseline to study endpoint and all other visits

  3. Vital signs

    Time frame: From baseline to study endpoint and all other visits

  4. Physical examination

    Time frame: From baseline to study endpoint and all other visits

07

Study locations

15 sites
  • Sanofi-Aventis
    North Ryde, Australia
  • Sanofi-Aventis
    Brussels, Belgium
  • Sanofi-Aventis
    Prague, Czech Republic
  • Sanofi-Aventis
    Paris, France
  • Sanofi-Aventis
    Berlin, Germany
  • Sanofi-Aventis
    Milan, Italy
  • Sanofi-Aventis
    Gouda, Netherlands
  • Sanofi-Aventis
    Warsaw, Poland
  • Sanofi-Aventis
    Porto Salvo, Portugal
  • Sanofi-aventis
    Bucharest, Romania
  • Sanofi-Aventis
    Bratislava, Slovakia
  • Sanofi-Aventis
    Barcelona, Spain
  • Sanofi-Aventis
    Stockholm, Sweden
  • Sanofi-Aventis
    Meyrin, Switzerland
  • Sanofi-Aventis
    Guildford, United Kingdom
08

References and documents

Publications

  • Fritsche A, Hahn A, Landgraf W, Haring HU. Incidence of Hypoglycaemia in Patients with Type 2 Diabetes - A Subgroup Analysis from the GINGER study. Eur Endocrinol. 2013 Mar;9(1):1-3. doi: 10.17925/EE.2013.09.01.1. Epub 2013 Apr 4. PubMed 30349602 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2004 and a primary completion of Nov 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 15, 2005
Start
Nov 2004
Primary completionActual
Nov 2007
Last update
Sep 15, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00174668
Lead sponsor
Sanofi
First posted
Sep 15, 2005
Start date
Nov 2004
Primary completion
Nov 2007
Last update
Sep 15, 2009

Study contacts

Valérie Pilorget, MD
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin glulisine · Insulin Glargine

Start the discussion